Loading...
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
Lemborexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia and is under investigation for treating other sleep disorders. Here we summarize pharmacokinetic, pharmacodynamic, and safety data from 3 randomized, double‐blind, placebo‐controlled phase 1 studies: single asc...
Na minha lista:
| Udgivet i: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891412/ https://ncbi.nlm.nih.gov/pubmed/32468649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.817 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|